|
מבוסס על מאמרן של ד"ר אלה פישמן ו Haya Lorberboum-Galski
The immunogenicity of the toxin moiety
of the chimeric protein can also be reduced by adapting various techniques like mutagenesis. Keeping these points in mind, the clinical application of this chimeric protein becomes an effective anti-allergy treatment. The cyto-toxicity of such fusion proteins can lead to an attractive treatment option of diseases like cancer etc.
למאמר המלא...
|
|
מבוסס על מאמרים של ד"ר אלה פישמן, , D. PRUS*, R. BELOSTOTSKY & H. LORBERBOUM-GALSKI
This chimeric protein can be developed as new generation treatment as it shows clinical superiority over other major groups of drugs like 2-agonists, methylxantines, glucocorticoids, antihistamines and chromolyn sodium etc. which are unable to prevent the allergic reaction and can only reverse or block its effects and also have side-effects. The use of similar chimeric molecules will offer a new hope for treat
למאמר המלא...
|
|
מבוסס על מאמרם של ד"ר אלה פישמן, Andrei V Budanov, Tzipora Shoshani, Alexander Faerman, Elena Zelin, Iris Kamer, Hagar Kalinski, Svetlana Gorodin, Ayelet Chajut, Paz Einat, Rami Skaliter, Andrei V Gudkov, Peter M Chumakov and Elena Feinstein
Therefore Hi95 is linked to the regulation of cell growth and survival. The characterization of Hi95 helps researchers in finding out novel therapeutics against stroke and heart attack. Thus the identification of various cell signaling pathways that are re
למאמר המלא...
|